Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study

BACKGROUND: Metastatic breast cancer (MBC) is an incurable disease and its treatment focuses on prolonging patients’ (pts) overall survival (OS) and improving their quality of life. Eribulin is a microtubule inhibitor that increases OS in pre-treated MBC pts. The most common adverse events (AEs) are...

Descripción completa

Detalles Bibliográficos
Autores principales: La Verde, Nicla, Damia, Giovanna, Garrone, Ornella, Santini, Daniele, Fabi, Alessandra, Ciccarese, Mariangela, Generali, Daniele Giulio, Nunzi, Martina, Poletto, Elena, Ferraris, Elisa, Cretella, Elisabetta, Scandurra, Giuseppa, Meattini, Icro, Bertolini, Alessandro Stefano, Cavanna, Luigi, Collovà, Elena, Romagnoli, Emanuela, Rulli, Eliana, Legramandi, Lorenzo, Guffanti, Federica, Bramati, Annalisa, Moretti, Anna, Cassano, Alessandra, Vici, Patrizia, Torri, Valter, Farina, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615373/
https://www.ncbi.nlm.nih.gov/pubmed/36307826
http://dx.doi.org/10.1186/s13058-022-01560-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615373/
https://www.ncbi.nlm.nih.gov/pubmed/36307826
http://dx.doi.org/10.1186/s13058-022-01560-w

Ejemplares similares